Dee E Silver Selected Research

Selegiline (E250)

2/2011	Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease.
1/2010	Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dee E Silver Research Topics

Disease

9	Parkinson Disease (Parkinson's Disease) 02/2017 - 07/2004
1	Dyskinesias (Dyskinesia) 02/2017
1	Hypokinesia (Bradykinesia) 09/2011
1	Edema (Dropsy) 01/2010
1	Hallucinations (Hallucination) 01/2010
1	Disorders of Excessive Somnolence (Hypersomnia) 01/2010
1	Disruptive, Impulse Control, and Conduct Disorders (Kleptomania) 01/2010

Drug/Important Bio-Agent (IBA)

3	Levodopa (L Dopa)FDA LinkGeneric 02/2017 - 07/2004
3	levodopa drug combination carbidopa (Nakom)FDA LinkGeneric 02/2017 - 04/2015
2	Selegiline (E250)FDA LinkGeneric 02/2011 - 01/2010
1	Delayed-Action PreparationsIBA 02/2017
1	SilverIBA 04/2016
1	Carbidopa (Lodosyn)FDA LinkGeneric 04/2016
1	Pharmaceutical PreparationsIBA 09/2011
1	rasagiline (Azilect)FDA Link 09/2011
1	Pramipexole (Mirapex)FDA LinkGeneric 01/2010
1	ropinirole (Requip)FDA LinkGeneric 01/2010
1	Dopamine Agonists (Dopamine Agonist)IBA 01/2010
1	amsonic acid (DAS)IBA 01/2010

Therapy/Procedure

3	Therapeutics 02/2017 - 08/2008
1	Drug Therapy (Chemotherapy) 02/2017
1	Long-Term Care 01/2007